Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | TACR2 | P21452 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29311925 | 1.00 | TYR (0.48) | TYRALOX5PTGS2ESR1ADRA2A | |
| SCHEMBL29311917 | 1.00 | TYR (0.48) | TYRALOX5PTGS2ESR1ADRA2A | |
| SCHEMBL13427739 | 1.00 | TYR (0.48) | TYRALOX5PTGS2ESR1ADRA2A | |
| SCHEMBL7607107 | 1.00 | TYR (0.48) | TYRALOX5PTGS2ESR1ADRA2A | |
| SCHEMBL12134619 | 1.00 | TYR (0.48) | TYRALOX5PTGS2ESR1ADRA2A | |
| SCHEMBL29311924 | 0.98 | TYR (0.46) | TYRALOX5PTGS2ESR1ADRA2A | |
| SCHEMBL29311921 | 0.91 | HPGD (0.45) | TYRALOX5KDM4EALDH1A1HSD17B10 | |
| SCHEMBL11334404 | 0.84 | TYR (0.43) | TYRALOX5PTGS2ESR1ADRA2A | |
| SCHEMBL9235513 | 0.83 | FASN (0.35) | TYRALOX5KDM4EALDH1A1 | |
| SCHEMBL7328264 | 0.82 | ALOX5 (0.36) | TYRALOX5ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037350-B2 | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-1933821-B1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-7432305-B2 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | EDISON PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432305-B2 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | EDISON PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| WO-2007035496-A1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | EDISON PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070072943-A1 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072943-A1 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037350-B2 | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia | FH, COQ8A, TFAM | TYR 2363/4885ALOX5 1404/4885PTGS2 951/4885 |
| US-20070072943-A1 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | FH, NDUFAB1, ECHS1 | TYR 1609/4885ALOX5 1702/4885PTGS2 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.